Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,401–15,500 of 15,747
Rabeau, A., Lavesque, J., Joseph, C., Cortot, A. B., & Mazières, J. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00108-7 · Cited by 2
Shen, C., Lin, Y.-P., Chen, W., Cheng, M.-H., Hong, J.-J., Hu, S.-Y., Shen, C., & Cheng, C. (2024) · Vaccines · doi:10.3390/vaccines12060658
Ratree, S., Assavapokee, N., Santibenchakul, S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342303
Ciomaga, B.-F., Pascu, C., & Ionescu, G. O. (2022) · Romanian Archives of Microbiology and Immunology · doi:10.54044/rami.2022.03.02
Miyakawa, K., Kubo, S., Jeremiah, S. S., et al. (2021) · medRxiv · doi:10.1101/2021.09.27.21264013
“Vaccines are the only limiting modality [1].”
Association between vaccination uptake, vaccine type, and long COVID in rural Indonesia
Sujarwoto, S., Holipah, H., Andarini, S., Aknuranda, I., Sahputri, R. A. M., Sarwono, A., Kusharyanto, P. G., Kusumo, B. E., & Maharani, A. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1598246 · Cited by 1
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0011
Capel, E. A., & Insfran, L. A. M. (2022) · Actualización en Medicina de Familia · doi:10.55783/amf.s181101
Li, J., Pan, Y., Han, Y., Zhou, C., Zhao, L., & He, Y. O. (2026) · medRxiv · doi:10.64898/2026.07.02.26357163
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1295
Immune Mechanisms and Translational Study Design in Viral Vaccine Development
Lim, S., & Martina, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135790
“It also provided clear examples of accelerated clinical development, with mRNA and adenoviral-vectored vaccines showing efficacy in large phase 3 trials within the first year of the pandemic [4–6].”
Coronaimpfung nicht risikofrei, aber im Vergleich zu COVID-19 harmlos
Gillissen, A. (2021) · Pneumo News · doi:10.1007/s15033-021-2775-z
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie · doi:10.1002/ange.202523579
Imagination and Idealism After the COVID-19 Pandemic
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0005
Yao, L., Megyesi, Z., Lehmann, P. V., & Kirchenbaum, G. A. (2026) · Vaccines · doi:10.3390/vaccines14070604 · Cited by 1
“These vaccines potently elicited neutralizing antibody reactivity in both naïve and convalescent subjects [20–23].”
Duyver, E., VELDE, T. V. D., Razooqi, D., Versluys, K. J. J., PETROVIC, M., & Noortgate, N. J. V. D. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.033
Kugeler, K. J., Williamson, J., Curns, A. T., Healy, J. M., Nolen, L. D., Clark, T. A., Martin, S. W., & Fischer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264179
“6% was used for both mRNA vaccines in the calculator [4, 5], while 66.”
BackgroundMethodInfluentialMatsuzono, K., Mieno, M., Mashiko, T., Anan, Y., Ozawa, T., Koide, R., Tanaka, R., Kimura, A., & Fujimoto, S. (2024) · SAGE Open Medicine · doi:10.1177/20503121241272518
“12, 13 Both mRNA vaccines showed high effectiveness and safety in clinical trials involving large populations; thus, they were distributed among the general population.”
BackgroundTargeted Degradation of PCNA Outperforms Stoichiometric Inhibition to Result in Programed Cell DeathPreprint
Chang, S. C., Gopal, P., Lim, S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065076
High-density Lipoprotein Inspired Lipid Nanoparticles for Systemic RNA delivery to the Brain
Xu, Z., Shalin, K., Do, V., Yan, A., & Gao, J. (2026) · doi:10.64898/2026.05.29.728695 · Cited by 1
“In addition, HLNP 65, 72 and 105 showed pronounced enrichment of vitronectin compared with HLNP 9, 13 and Pati.”
Bringing Nuance to Autonomy-Based Considerations in Vaccine Mandate Debates
Blumenthal‐Barby, J. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780192871688.003.0005
Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis
Fan, H., Tan, Y., Zhang, J., Liu, X., Qu, J., Chua, D., Cheng, H. S., Kim, J. H. S., Liu, Y. X., Qin, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202501909 · Cited by 2
Death Despite COVID-19 Vaccine: Case Report
GÜNER, N. G., Durmuş, E., Güneysu, F., Yürümez, Y., & Aslan, N. (2021) · Phoenix Medical Journal · doi:10.38175/phnx.936059
“1% protective 14 days after the second dose, and the BNT162b2 vaccine was announced to be protective against 95% COVID-19 disease seven days after the second dose (7,8).”
BackgroundIndia’s COVID-19 Vaccination Drive: Its Relevance in Managing the Pandemic
Pramanik, S., & Motheram, A. (2023) · India studies in business and economics · doi:10.1007/978-981-99-4906-9_10
Lanthier, L., Carignan, A., Plourde, M.-É., et al. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.02.001
Optimal Control of High-Risk Data Using the Convex Structured Method
Zhu, B., Qiu, D., & Xie, J. (2025) · International Journal of Fuzzy Systems · doi:10.1007/s40815-025-02038-5
Akhrass, F. A., Reynolds, N., Akhrass, C. A., Dawahare, J. H., Raj, R., Green, G., & Hom, R. C. (2021) · Research Square · doi:10.21203/rs.3.rs-612401/v1 · Cited by 1
Covid-19: What the pandemic has taught us and the way forward
Guleria, R., & Agarwal, S. (2023) · The National Medical Journal of India · doi:10.25259/nmji_1064_22
Ha, M., Kim, J., Kim, S., Naidu, G. S., Cho, S., & Yong, S.-B. (2026) · Advancement of science · doi:10.1002/advs.77923
Wang, X., Tian, Z., Benitez, A. P., Bian, X., Vaidya, A., Guerrero, E. D., Sun, Y., Zhang, C., Duan, Y., Wei, J., et al. (2026) · Nature Chemical Engineering · doi:10.1038/s44286-026-00425-9 · Cited by 2
COVID-19 Vaccine Take-up Rate, Safety and Tolerability in Patients with Epilepsy
Tokuç, F. E. U., Genç, F., & Gömceli, Y. B. (2023) · Archives of Epilepsy · doi:10.4274/archepilepsy.2023.224247
Hama, Y., & Tate, E. (2021) · Libyan Journal of Medical Sciences · doi:10.4103/2588-9044.338635
新型コロナウイルス(COVID-19)ワクチンの供給:世界的危機へのグローバルなアプローチ
OECD (2021) · Singata korona wairusu (Covid-19) he no OECD seisaku tai'ō · doi:10.1787/00fc8ca0-ja
Fucà, G., Lecchi, M., Ciniselli, C. M., Ottini, A., Spagnoletti, A., Mazzeo, L., Morelli, D., Frati, P., Stroscia, M., Ebrahem, E., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221108687
COVID-19 vaccination might be associated with asymmetric thyroid eye disease
Matsuzawa, K., Izawa, S., Yunaga, H., Kihara, S., Kadowaki, K., Fukaya, K., Matsumoto, K., Nagata, K., Okura, T., Miyazaki, D., et al. (2024) · Thyroid Science · doi:10.1016/j.thscie.2024.100019
Tỷ lệ nhiễm SARS-CoV-2 sau tiêm vắc xin phòng COVID-19 tại tỉnh Bắc Ninh, Việt Nam, năm 2021
Lộc, P. Q., Vân, H. T. H., Hương, Đ. T., Quang, N. N., & Giang, L. M. (2023) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v167i6.1665 · Cited by 1
“Cùng loại vắc xin ở tất cả các mũi 956 (97,4) 224.”
Vaccination identification system using raspberry Pi
Kiran, K. K., Velamala, P. K., Nuthibilli, K., et al. (2023) · i-manager’s Journal on Electronics Engineering · doi:10.26634/jele.13.2.19474
RNA-Based vaccine manufacturing: infrastructure, regulations, and global implications
Fonseca, L. M. D. S., Junior, V., Santos, H. M., Ferreira, C. V., Ferreira, C. V., Moret, M. A., Mascarenhas, L., Andrade, L. P. C. D. S., Minafra, C., & Machado, B. A. S. (2024) · Concilium · doi:10.53660/clm-3202-24g02 · Cited by 1
Dabas, R., Navaratnam, N., Iino, H., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4995024
Probing the conformational changes of in vivo overexpressed cell cycle regulator 6S ncRNA
Makraki, E., Miliara, S., Pagkalos, M., Kokkinidis, M., Mylonas, E., & Fadouloglou, V. E. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1219668
Sonnleitner, S., Sonnleitner, S. T., Obererlacher, S., & Walder, G. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.115007
de Faria, C. D., Neto, F. A. R. S., Machado, Y. D. J., Santos, R. A. D. S. E., Batista, L. B. C. A. M., Sampaio, C. J. S., Santiago, R. D., Esteves, J. F., de Souza, R. A., & Silva, R. D. B. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n6-282 · Cited by 1
(2021) · doi:10.1101/2021.11.01.21265737
Jin, T., Xu, G., Zhou, W., Shi, Y., & Wang, H. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70954
Chen, X., Agarwal, S., Hoelscher, S., Egan, R., Jaiswal, D., Stassinopoulos, A., Reed, R., McClure, J., & Kroll, W. (2021) · medRxiv · doi:10.1101/2021.05.06.21256544
Long-term adverse effects following COVID-19 vaccination
Aldali, J. A., & Meo, S. A. (2026) · Medicine · doi:10.1097/md.0000000000050282
From Misinformation to Meaning: Trust, Truth, and Turbulence in Healthcare Communication Ecosystems
Ray, K. S. S. S. (2025) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem48285 · Cited by 1
Zamora, J. I., López-Martínez, M., Patricio-Liébana, M., León-Román, J. C., Bermejo, S., Vergara, A., Agraz, I., Ramos-Terrades, N., Azancot, M. A., Toapanta, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062420 · Cited by 1
Contreras-Villa, J., Martinez, G. R., Parra‐Ortega, I., Romo-Castillo, M., Cortés-Sarabia, K., Saldaña‐Ahuactzi, Z., Flores-Alanis, A., Aureoles-Romero, A., Salazar–García, M., González, J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12038-3
Xu, Y., Zhang, X.-B., & Zhang, J.-P. (2026) · Human Gene Therapy · doi:10.1177/10430342261454725
Increasing Lipid Nanoparticle mRNA Copy Number Improves Transfection Potency
Zhang, Y., Leung, J., Cheng, J., Momeni, A., Kamanzi, A., Bido, A. T., Liao, S., Kang, E., Strong, C., Kastrup, C. J., et al. (2026) · Advanced Materials · doi:10.1002/adma.75174
Wan, D., Li, L., He, F., Wang, M., Jia, S., Zhang, P., Wang, J., Yang, J., Zhang, Y. Y., Ji, B., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.03797-25
“Numer ous vaccines targeting the original SARS-CoV-2 strain have received emergency use authorization globally (36–38).”
A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferretsPreprint
Martins, M., do Nascimento, G. M., Conforti, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510112
Dude, C. M., Badell, M. L., & Jamieson, D. J. (2023) · Wiley eBooks · doi:10.1002/9781119636540.ch31
Garrett, N., Tapley, A., Hudson, A., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4890648
Bailey, S. F., & Akter, M. (2022) · Springer eBooks · doi:10.1007/978-981-19-1356-3_5
Vasileios Spyropoulos, M. S., Agathi Spiropoulou, M. S., Spyropoulou, G., et al. (2021) · Archives of Pulmonology and Respiratory Medicine · doi:10.22259/2639-362x.0401004
Nanostructured lipid-based adjuvants and delivery systems for antiviral vaccine development
Zhao, Y., Cheng, Z., Cai, D., Fang, Y.-L., Xu, J., Dai, H., Liu, W., & Zhang, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112059
Shahan, J., Collins, R. H., Patel, P. A., Madanat, Y. F., & Vusirikala, M. (2023) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2023.14.5.2
Reporting of AstraZeneca studies may have caused vaccine reservations
Bignardi, G. E. (2021) · BMJ · doi:10.1136/bmj.n937
A Case of Acute Hepatitis B Accompanied by COVID-19 Infection
Kaya, A., Şahin, N. A., Tunç, A., et al. (2023) · Viral Hepatitis Journal · doi:10.4274/vhd.galenos.2023.2023-4-4
The Effect of Covid-19 Vaccines on Peripheral Arterial Disease
Eroglu, O., Anasız, H., & Özceylan, G. (2024) · Eurasian Journal of Family Medicine · doi:10.33880/10.33880/ejfm.2024130404
Razak, M. K. A., Jebur, A. A. A. R., Hamdan, B. J. A., & Ibrahim, A. K. (2023) · medRxiv · doi:10.1101/2023.01.20.23284814
Clarke, K. S. P., Stewart, A. T., Sinclair, E. L., Lewis, R., Labeed, F. H., Dunn‐Walters, D. K., & Hughes, M. P. (2025) · Scientific Reports · doi:10.1038/s41598-025-08724-6
Basutkar, R. S., Murugan, S., Priyan, S., et al. (2023) · Coronaviruses · doi:10.2174/0126667975269133231117062158
(2023) · doi:10.1101/2023.08.22.23294414
“While the safety and efficacy of the vaccines have been proven in controlled studies and are expected to reduce morbidity and mortality, there is an irrefutable need for further evidence of the effectiveness of the vaccines in preventing severe illness and death from COVID-19 in the real world (7-21).”
BackgroundVidal, M. S., Tantengco, O. A. G., & Amosco, M. D. (2023) · Philippine Journal of Obstetrics and Gynecology · doi:10.4103/pjog.pjog_49_23
Duarte, R. A., Soares, R., Lu, I., Ferrer, F. A. D., Gama, P., Gonçalves, H., Lopes, K., Sofia, F., Cortes, C., & Lobos, A. V. (2022) · EMJ Nephrology · doi:10.33590/emjnephrol/10023287
COVID-19 Vaccination and Lethality Reduction: A Prospective Cohort Study in VenezuelaPreprint
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña-Ávila, Ó. D., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., González, R. D. C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3813947/v1
Vaccination on SIR model of Covid-19 using backstepping control
Mu’tamar, K., Naiborhu, J., & Saragih, R. (2023) · AIP conference proceedings · doi:10.1063/5.0103444 · Cited by 1
Amphiphilic dendrimers for nucleic acid delivery
Chen, J. (2021) · theses.fr (ABES) · doi:10.70675/9c958469z36faz4c64zb727z584addf9de34 · Cited by 1
EMJ COVID-19 monthly top five (June 2021)
Chatha, R., Reed, M., Jennings, H., McClatchey, A., Shahin, A., Williamson, C., McGowan, B., & Oliver, G. J. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-211796
Follow-Up of Side Effects throughout the Entire Course of Coronavirus Vaccination
Odeh, M. M., Al-Jussani, G. N., Ashour, A. A., AlNaqah, H., Hasan, H. A., Sbitan, L., Dawabsheh, A., & Alhawi, M. (2023) · Vaccines · doi:10.3390/vaccines11030704
“The categories for side effects [19] were classified as mild (i.”
BackgroundResultInfluentialBorges, M. C., Palácios, R., Conde, M. T. R. P., Volpe, G. J., Ferreira, N. N., Garibaldi, P. M. M., da Fonseca, B. A. L., Calado, R. T., Coutinho, B. M., Gomes, B. B. M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-37815-1 · Cited by 1
CME: L’hypertension artérielle et la pandémie COVID-19: Ce qu’il faut retenir en pratique médicale
Wuerzner, G., & Waeber, B. (2021) · Praxis · doi:10.1024/1661-8157/a003639
Rao, B., Wang, L., Yang, M., et al. (2024) · Virulence · doi:10.1080/21505594.2024.2310450
“Overall, although other vaccines appeared to have higher antibody positive rates after vaccination [22,23], the immunogenicity of CoronaVac was also excellent to some extent.”
BackgroundOn the Safety of COVID-19 Vaccine Prophylaxis in Rheumato- logical Patients: Results and Prospects
Belov, B. S., Muravyevа, N. V., & Perepechaeva, O. B. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-1-2-100-112
Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation
Crodel, C. C., Gork, L., Göpel, W., Linke, P., Sinn, K., Miethke, J., Hochhaus, A., & Hilgendorf, I. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06632-4
Circular RNA hsa_circ_0002473 Boosts Gastric Cancer Progression via the miR-873-5p/TEAD1 Axis
Wang, M., Wu, Z., Tong, R., Geng, Y., Li, F., Huo, X., & Yu, L. (2026) · Biochemical Genetics · doi:10.1007/s10528-026-11407-0
“Building on the success of RNA vaccines against COVID-19 (References (Polack et al. 2020)), circRNA-based immunotherapeutic strategies, such as LNP-encapsulated circRNAs have shown potent antitumor effects in preclinical models (References (Li et al. 2022)), offering novel avenues for GC treatment.”
How effective is the first shot of the Pfizer or Moderna vaccine?
Petri, W. (2021) · The Conversation · doi:10.64628/aai.jtw76xsde · Cited by 2
COVID-19 vaccines-related dermatological manifestations
Pathania, Y. S. (2025) · Cosmoderma · doi:10.25259/csdm_88_2025
Assessment of multiple domains of pain following BNT162b2 mRNA COVID-19 vaccination
Izumi, M., Morimoto, T., Oda, S., et al. (2023) · The Journal of Medical Investigation · doi:10.2152/jmi.70.355
Active and Passive Immunization Approaches in Transplant Recipients
Ringer, M., Azar, M. M., & Malinis, M. F. (2023) · Current Transplantation Reports · doi:10.1007/s40472-023-00406-4 · Cited by 1
“Both vaccines are based on mRNA technology encoding the SARS-CoV-2 spike protein [2, 3].”
Attitudes of Primary Health Care patients towards COVID-19 vaccinations
Karczmarz, S., Owczarczyk, A., Żuk, P., et al. (2024) · Medycyna Ogólna i Nauki o Zdrowiu · doi:10.26444/monz/184062
Vaccine Basics and the Development and Rollout of COVID-19 Vaccines
Mani, S., & Griffin, D. O. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00018-x
Ulcerating reaction in association with Pfizer‐BioNTech COVID ‐19 vaccine in an 11‐year‐old boy
Thrush, J., Polly, S. A., Anthony, J. S., Fernandez, J., Taylor, J. S., Preston, D. C., & Fernandez, A. P. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19460
Medical Interventions and Risk
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0009
Hueso, T., Godron, A.-S., Lanoy, E., Pakanowski, J., Levi, L. I., Gras, E., Surgers, L., Guemriche, A., Meynard, J., Pirenne, F., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3951140
Pituitary and COVID-19: review
Buyvalenko, U. V., Александровна, П. М., Алексеевна, З. Р., Belaya, Z. E., & Mel'nichenko, G. A. (2022) · Problems of Endocrinology · doi:10.14341/probl13108 · Cited by 1
“Опубликованные в настоящее время данные не имеют информации о побочных эффектах вакцинации и о противопоказаниях к ней у пациентов с нейроэндокринными заболеваниями [70].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.